Csw Industrials, Inc.
CSW NYSE Adhesives & Sealants Financials FY2017βFY2026
What Csw Industrials, Inc. does
No business description yet.
- Legal name
- CSW INDUSTRIALS, INC.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K Β· May 26, 2026
- Accession Β· CIK
- 0001624794-26-000027
0001624794
Revenue and margins
Csw Industrials, Inc. had $1.1B of revenue in fiscal 2026, up 23.3% on the year before.
Net income and earnings per share
From fiscal 2017 to 2026, diluted EPS grew 28.5% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $132M in fiscal 2026, 12.2% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Csw Industrials, Inc. returned $151M to shareholders in fiscal 2026, 114% of free cash flow. The diluted share count rose 2.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably Csw Industrials, Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $16.6M | $18.5M | $22.2M | $226M | $33.8M |
| Debt incl. finance leases | $253M | $253M | $166M | $872M | $858M |
| Net debt / EBITDA | 1.8x | 1.3x | 0.7x | 2.9x | 4.5x |
| Debt / equity | 0.5x | 0.5x | 0.3x | 0.8x | 0.8x |
| Current ratio | 2.6x | 3.0x | 2.9x | 4.0x | 2.6x |
| Quick ratio | 1.3x | 1.5x | 1.6x | 2.7x | 1.2x |
| Total assets | $995M | $1.0B | $1.0B | $1.4B | $2.3B |
| Total liabilities | $511M | $499M | $408M | $287M | $1.2B |
| Shareholders' equity | $469M | $526M | $616M | $1.1B | $1.1B |
| Net debt (β = net cash) | $236M | $235M | $144M | $646M | $824M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 6 / 9 | 8 / 9 | 6 / 9 | 5 / 9 | 6 / 9 | 9 / 9 | 7 / 9 | 6 / 9 | 4 / 9 |
| Accruals ratio | β7.0% | β14.9% | β4.1% | β6.7% | β4.2% | β0.3% | β2.5% | β6.0% | β2.6% | β2.0% |
| Altman Z'' | 6.60 | 8.52 | 8.77 | 8.74 | 3.71 | 4.16 | 4.89 | 5.79 | 8.60 | 3.52 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $287M | $326M | $350M | $386M | $419M | $626M | $758M | $793M | $878M | $1.1B |
| Gross profit | $129M | $148M | $161M | $177M | $185M | $256M | $318M | $351M | $393M | $454M |
| Research and development | β | β | β | β | β | β | $4.8M | $5.9M | $5.3M | $5.8M |
| Operating income | $32.0M | $49.7M | $60.4M | $65.9M | $59.2M | $97.4M | $139M | $159M | $181M | $169M |
| Pretax income | $32.2M | $48.2M | $61.4M | $57.4M | $50.9M | $91.5M | $126M | $140M | $180M | $146M |
| Income tax | $14.4M | $15.6M | $15.4M | $12.7M | $10.8M | $24.1M | $29.3M | $37.9M | $42.6M | $32.7M |
| Net income | $11.1M | β$11.9M | $45.6M | $45.7M | $40.1M | $66.4M | $96.4M | $102M | $137M | $112M |
| Diluted EPS | $0.70 | β$0.76 | $2.93 | $3.01 | $2.65 | $4.20 | $6.20 | $6.52 | $8.38 | $6.70 |
| Diluted shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | $39.0M | $43.2M | $59.7M | $69.9M | $66.3M | $69.1M | $121M | $164M | $168M | $150M |
| Capital expenditure | $6.9M | $5.5M | $7.5M | $11.4M | $8.8M | $15.7M | $14.0M | $16.6M | $16.3M | $17.3M |
| Free cash flow | $32.2M | $37.6M | $52.2M | $58.5M | $57.4M | $53.4M | $108M | $148M | $152M | $132M |
| Depreciation and amortization | $13.8M | $14.9M | $13.8M | $14.6M | $22.7M | $36.4M | $35.0M | $38.3M | $42.2M | $15.9M |
| Stock-based compensation | $2.8M | $3.7M | $3.9M | $5.1M | $5.1M | β | β | β | β | β |
| Share buybacks | $1.0M | $2.2M | $46.7M | $28.5M | $10.5M | $19.3M | $39.1M | $15.3M | $27.7M | $133M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $8.1M | $8.1M | $9.5M | $10.6M | $11.8M | $14.6M | $18.0M |
| Dividends and buybacks | $1.0M | $2.2M | $46.7M | $36.6M | $18.6M | $28.8M | $49.6M | $27.1M | $42.3M | $151M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $23.1M | $11.7M | $26.7M | $18.3M | $10.1M | $16.6M | $18.5M | $22.2M | $226M | $33.8M |
| Total debt | $73.2M | $24.0M | $31.5M | $10.9M | $242M | $253M | $253M | $166M | $872M | $858M |
| Current assets | $147M | $128M | $151M | $150M | $219M | $300M | $323M | $331M | $593M | $589M |
| Current liabilities | $38.5M | $44.9M | $49.2M | $59.1M | $82.7M | $117M | $108M | $116M | $147M | $227M |
| Inventory | $43.7M | $43.0M | $51.4M | $58.6M | $103M | $150M | $162M | $151M | $195M | $310M |
| Property and equipment, net | $56.8M | $54.5M | $53.6M | $57.2M | $82.6M | $87.0M | $88.2M | $92.8M | $93.4M | $108M |
| Goodwill | $80.9M | $81.8M | $86.3M | $91.7M | $219M | $225M | $243M | $247M | $264M | $633M |
| Intangible assets | $59.3M | $53.1M | $50.5M | $46.2M | $283M | $301M | $319M | $319M | $358M | $900M |
| Total assets | $398M | $341M | $353M | $374M | $880M | $995M | $1.0B | $1.0B | $1.4B | $2.3B |
| Total liabilities | $126M | $75.1M | $88.9M | $92.5M | $464M | $511M | $499M | $408M | $287M | $1.2B |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $272M | $266M | $267M | $280M | $415M | $469M | $526M | $616M | $1.1B | $1.1B |
| Margins | ||||||||||
| Gross margin | 44.9% | 45.3% | 46.1% | 45.8% | 44.0% | 40.9% | 42.0% | 44.2% | 44.8% | 41.9% |
| Operating margin | 11.1% | 15.2% | 17.3% | 17.1% | 14.1% | 15.5% | 18.3% | 20.1% | 20.6% | 15.6% |
| EBITDA margin | 15.9% | 19.8% | 21.2% | 20.9% | 19.5% | 21.4% | 23.0% | 24.9% | 25.4% | 17.0% |
| Net margin | 3.9% | β3.6% | 13.0% | 11.8% | 9.6% | 10.6% | 12.7% | 12.8% | 15.6% | 10.4% |
| FCF margin | 11.2% | 11.5% | 14.9% | 15.2% | 13.7% | 8.5% | 14.2% | 18.6% | 17.3% | 12.2% |
| Returns | ||||||||||
| Return on capital | 6.5% | 12.1% | 16.6% | 18.8% | 7.2% | 10.2% | 14.0% | 15.3% | 8.1% | 7.0% |
| Return on capital employed | 8.9% | 16.8% | 19.9% | 20.9% | 7.4% | 11.1% | 14.9% | 17.2% | 14.7% | 8.1% |
| Return on equity | 4.1% | β4.4% | 17.1% | 16.7% | 11.5% | 15.0% | 19.4% | 17.8% | 16.2% | 10.6% |
| Return on assets | 2.8% | β3.2% | 13.1% | 12.6% | 6.4% | 7.1% | 9.5% | 9.7% | 11.3% | 6.1% |
| Return on tangible equity | 8.4% | β9.1% | 34.9% | 32.1% | β | β | β | 204.5% | 30.4% | β |
| Growth | ||||||||||
| Revenue growth | β | 13.5% | 7.3% | 10.2% | 8.6% | 49.4% | 21.0% | 4.6% | 10.8% | 23.3% |
| Net income growth | β | β207.3% | β | 0.3% | β12.3% | 65.6% | 45.3% | 5.4% | 34.4% | β18.0% |
| EPS growth | β | β208.6% | β | 2.7% | β12.0% | 58.5% | 47.6% | 5.2% | 28.5% | β20.0% |
| FCF growth | β | 17.0% | 38.7% | 12.0% | β1.8% | β6.9% | 101.2% | 37.4% | 2.9% | β13.0% |
| Share count change | β | β1.1% | β0.9% | β2.1% | β0.5% | 4.5% | β1.7% | 0.2% | 4.7% | 2.4% |
| Financial health | ||||||||||
| Net debt / EBITDA | 1.1x | 0.2x | 0.1x | β0.1x | 2.8x | 1.8x | 1.3x | 0.7x | 2.9x | 4.5x |
| Debt / equity | 0.3x | 0.1x | 0.1x | 0.0x | 0.6x | 0.5x | 0.5x | 0.3x | 0.8x | 0.8x |
| Current ratio | 3.8x | 2.8x | 3.1x | 2.5x | 2.6x | 2.6x | 3.0x | 2.9x | 4.0x | 2.6x |
| Quick ratio | 2.7x | 1.9x | 2.0x | 1.5x | 1.4x | 1.3x | 1.5x | 1.6x | 2.7x | 1.2x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.4% | 1.7% | 2.1% | 3.0% | 2.1% | 2.5% | 1.8% | 2.1% | 1.9% | 1.6% |
| Stock comp / revenue | 1.0% | 1.1% | 1.1% | 1.3% | 1.2% | β | β | β | β | β |
| Payouts / FCF | 3.1% | 6.0% | 89.5% | 62.6% | 32.3% | 53.8% | 46.2% | 18.3% | 27.8% | 113.9% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 6.0 | 8.0 | 6.0 | 5.0 | 6.0 | 9.0 | 7.0 | 6.0 | 4.0 |
| Altman Z'' | 6.6 | 8.5 | 8.8 | 8.7 | 3.7 | 4.2 | 4.9 | 5.8 | 8.6 | 3.5 |
| Accruals ratio | β7.0% | β14.9% | β4.1% | β6.7% | β4.2% | β0.3% | β2.5% | β6.0% | β2.6% | β2.0% |
Source: SEC EDGAR XBRL filings (CIK 0001624794). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.